Metastasis
Author:
Mikael Häggström [note 1]
Contents
Primary tumor versus metastasis

Indications of a metastasis rather than primary tumor are mainly:
- Tumors that are unlikely to arise at the location at hand.
- Tumors conforming to more likely metastasis pathways.
If a suspected malignancy is present, generally check the patient history for any history of cancer, especially for tumors in more common metastasis sites, which mainly include lung, bone, liver and/or brain. In case of such history, preferably look at the microscopy slides of the past cancer to help determining whether the current case is of the same origin, versus a primary at the current body location, versus a metastasis of yet another location. If there is no known history of cancer, still consider a metastasis of unknown primary origin, especially for suspected malignancies in lymph nodes, liver, lungs, bones, or skin.[2]
Metastasis of unknown primary
Histopathologic type - see section below for descriptions[3] |
Relative incidence among metastases of unknown primary origin[3] |
Well and poorly differentiated adenocarcinomas | 50% |
Undifferentiated carcinoma | 30% |
Squamous cell carcinoma | 15% |
Undifferentiated neoplasms | 5% |
- Memorization-worthy:[note 2] Do not diagnose a renal cell carcinoma metastasis without radiologic evidence of a renal tumor. To be a plausible primary tumor for a renal cell carcinoma metastasis, a renal tumor should be visible radiologically. In cases of suspected renal cell carcinoma but no renal imaging is available, it is reasonable to ask the ordering doctor to allow you to wait with signing out the pathology report until renal radiology has been performed.
Undifferentiated malignancy
An initial panel of cytokeratin (CK, such as by CK AE1/AE3 cocktail), S100, vimentin and LCA (CD45) can be used (see source article for subsequent work-up).[4]
Alternatively, a more comprehensive panel can be performed upfront, with the most pertinent panel suggested below (with main associated primary origins in parentheses), but it should be tailored to additional clues from each individual case:[5]
- Mucicarmine (adenocarcinoma)
- CK7 and CK20 can give a broad indication of the primary site. Still use more specific immunohistochemistry stains instead or in addition where applicable. See table below for main patterns.
- NKX3.1 in males (prostate adenocarcinoma) or estrogen and progesterone receptor in females (female reproductive tract).
- TTF-1 (thyroid or lung tumor)
- GATA3 (urothelial carcinoma, breast tumor)
- CDX2 (gastrointestinal tumor)
- p63 (squamous cell carcinoma)
- S100 (neural, invasive melanoma)
- LCA (CD45) (hematopoietic)
- Synaptophysin (neuroendocrine)
CK20 | |||
---|---|---|---|
Positive | Negative | ||
CK7 | Positive |
|
|
Negative |
|
|
Further reading
Notes
- ↑ For a full list of contributors, see article history. Creators of images are attributed at the image description pages, seen by clicking on the images. See Patholines:Authorship for details.
- ↑ Further information on what is memorization-worthy or not: Learning pathology
Main page
References
- ↑ List of included entries and references is found on main image page in Commons: Wikimedia Commons: Metastasis sites for common cancers.svg
- ↑ Lymph nodes, liver, lungs, bones, or skin are the main sites of cancer of unknown primary origin (CUP):
{{cite web|url=https://www.mskcc.org/cancer-care/types/cancer-unknown-primary-origin%7Ctitle=Cancer of Unknown Primary Origin|website=Memorial Sloan Kettering Cancer Center|accessdate=20222-10-14 - ↑ 3.0 3.1 3.2 Collado Martín R, García Palomo A, de la Cruz Merino L, Borrega García P, Barón Duarte FJ, Spanish Society for Medical Oncology (2014). "Clinical guideline SEOM: cancer of unknown primary site. ". Clin Transl Oncol 16 (12): 1091-7. doi: . PMID 25392080. PMC: 4239766. Archived from the original. .
- ↑ Lin F, Liu H (2014). "Immunohistochemistry in undifferentiated neoplasm/tumor of uncertain origin. ". Arch Pathol Lab Med 138 (12): 1583-610. doi: . PMID 25427040. Archived from the original. .
- ↑ Partly inspired by:
Beauchamp K, Moran B, O'Brien T, Brennan D, Crown J, Sheahan K (2023). "Carcinoma of unknown primary (CUP): an update for histopathologists. ". Cancer Metastasis Rev. doi: . PMID 37394540. Archived from the original. . - ↑ Selves J, Long-Mira E, Mathieu MC, Rochaix P, Ilié M (2018). "Immunohistochemistry for Diagnosis of Metastatic Carcinomas of Unknown Primary Site. ". Cancers (Basel) 10 (4). doi: . PMID 29621151. PMC: 5923363. Archived from the original. .
- ↑ Elliot Weisenberg, M.D.. Esophagus - Carcinoma - Adenocarcinoma. Pathology Outlines. Last author update: 1 June 2013. Last staff update: 31 October 2022
Image sources